[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jupiter Neurosciences Inc (JUNS)

Jupiter Neurosciences Inc (JUNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,390
  • Shares Outstanding, K 36,281
  • Annual Sales, $ 20 K
  • Annual Income, $ -8,640 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.73
  • Price/Sales 252.32
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings $-0.06 on 05/14/26
  • Next Earnings Date 08/17/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1100 +10.00%
on 07/24/26
0.2982 -59.42%
on 06/26/26
-0.1320 (-52.17%)
since 06/24/26
3-Month
0.1100 +10.00%
on 07/24/26
0.5298 -77.16%
on 05/20/26
-0.2691 (-68.98%)
since 04/24/26
52-Week
0.1100 +10.00%
on 07/24/26
1.8395 -93.42%
on 09/30/25
-1.5490 (-92.75%)
since 07/24/25

Most Recent Stories

More News
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL,...

JUNS : 0.1210 (-20.92%)
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.1113 (+1.37%)
JUNS : 0.1210 (-20.92%)
MDMA.CN : 0.1600 (+3.23%)
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE)...

JUNS : 0.1210 (-20.92%)
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease

Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter...

JUNS : 0.1210 (-20.92%)
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position  Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:...

JUNS : 0.1210 (-20.92%)
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders...

JUNS : 0.1210 (-20.92%)
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“ PharmAla ” or the “ Company ”), a global leader in the research, development, and manufacturing...

MDXXF : 0.1113 (+1.37%)
JUNS : 0.1210 (-20.92%)
MDMA.CN : 0.1600 (+3.23%)
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May...

JUNS : 0.1210 (-20.92%)
MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1600 (+3.23%)
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announced...

JUNS : 0.1210 (-20.92%)
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will...

JUNS : 0.1210 (-20.92%)

Business Summary

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses...

See More

Key Turning Points

3rd Resistance Point 0.1873
2nd Resistance Point 0.1697
1st Resistance Point 0.1453
Last Price 0.1210
1st Support Level 0.1033
2nd Support Level 0.0857
3rd Support Level 0.0613

See More

52-Week High 1.8395
Fibonacci 61.8% 1.1788
Fibonacci 50% 0.9747
Fibonacci 38.2% 0.7707
Last Price 0.1210
52-Week Low 0.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.